Ahmed K A, Robbins K T, Wong F, Salazar J E
Department of Otolaryngology--Head and Neck Surgery, University of Tennessee, Memphis 38163, USA.
Laryngoscope. 2000 Nov;110(11):1789-93. doi: 10.1097/00005537-200011000-00002.
OBJECTIVES/HYPOTHESIS: To determine whether an aggressive approach using trimodality therapy would improve the outcome in head and neck cancer patients with advanced (N3) nodal disease.
In this retrospective, nonrandomized review, we analyzed a subset of patients who were treated in a targeted chemoradiation therapy protocol, consisting of 31 patients who received treatment between June 1993 and June 1997.
Patients received selective intra-arterial infusions of cisplatin (150 mg/m2/wk for 4 weeks) and concomitant radiation therapy (2 Gy/fraction x 35 daily fractions over a 7-wk period) to the primary and clinically positive nodal disease. The patients were re-evaluated 2 months later and underwent salvage neck dissections if there was any residual disease.
Classification of disease in the primary site was as follows: T1 in 2 patients, T2 in 6 patients, T3 in 14 patients, and T4 in 9 patients. Among the 31 patients who were assessed for response at the nodal site, 4 of 31 (13%) had a complete response, 21 of 31 (68%) had a partial response, and 1 of 31 (3%) had no response. Excluding the 5 patients who could not be evaluated, 4 of 26 patients (15%) had a complete response, 21 of 26 (81%) had a partial response, and 1 of 26 (4%) had no response. Nineteen patients subsequently underwent neck dissection, and five patients had histological evidence of residual disease. The remaining seven patients included four who had a complete response in their necks and three who died of intercurrent disease before re-staging. Among the 23 patients who were rendered disease free, there were no recurrences within the neck, whereas 1 patient had recurrence at the primary site and 11 patients had recurrence at distant sites. With a median follow-up of 15 months (range, 4-41 mo), the 3-year overall survival and disease-specific survival were 41% and 43%, respectively.
Targeted chemoradiation therapy followed by surgical salvage is a highly effective approach for regional control of patients with N3 nodal disease, whereas additional strategies are required to address the problem of distant metastases.
目的/假设:确定采用三联疗法的积极治疗方法是否能改善晚期(N3)颈部淋巴结疾病的头颈癌患者的治疗效果。
在这项回顾性、非随机研究中,我们分析了一组接受靶向放化疗方案治疗的患者,包括1993年6月至1997年6月期间接受治疗的31例患者。
患者接受顺铂选择性动脉内输注(150mg/m²/周,共4周),并对原发灶和临床阳性颈部淋巴结疾病进行同步放疗(2Gy/分次,每周5天,共35次,为期7周)。2个月后对患者进行重新评估,如有残留疾病则进行挽救性颈部清扫术。
原发部位疾病分类如下:2例为T1,6例为T2,14例为T3,9例为T4。在31例接受颈部淋巴结反应评估的患者中,31例中有4例(13%)完全缓解,31例中有21例(68%)部分缓解,31例中有1例(3%)无反应。排除5例无法评估的患者后,26例患者中有4例(15%)完全缓解,26例中有21例(81%)部分缓解,26例中有1例(4%)无反应。19例患者随后接受了颈部清扫术,5例患者有残留疾病的组织学证据。其余7例患者包括4例颈部完全缓解的患者和3例在重新分期前死于并发疾病的患者。在23例无疾病的患者中,颈部无复发,而1例患者在原发部位复发,11例患者在远处复发。中位随访15个月(范围4 - 41个月),3年总生存率和疾病特异性生存率分别为41%和43%。
靶向放化疗后行手术挽救是控制N3颈部淋巴结疾病患者局部病变的高效方法,而需要额外的策略来解决远处转移问题。